" class="no-js "lang="en-US"> Abbott - Medtech Alert
Sunday, June 09, 2024
Abbott | Pharmtech Focus


About Abbott


Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on Twitter @AbbottNews.

We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce.

Related Story

Abbott Announces US and European Approvals for New Technologies to Support Effective Treatment for Abnormal Heart Rhythms

February 3 2023

Abbott has announced two approvals as part of its growing suite of electrophysiology products in […]

Abbott Announces European Launch of Amplatzer™ Talisman™ System to Close Hole in Heart for People at Risk of Recurrent Stroke

September 9 2022

Abbott today announced the European launch of its Amplatzer™ Talisman™ PFO Occlusion System to treat […]

FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions

August 24 2022

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved its […]

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

August 12 2022

A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict […]

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

June 6 2022

Abbott (NYSE: ABT) today announced it’s developing a new biowearable that will continuously monitor glucose and […]

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

May 20 2022

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally […]

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise

May 5 2022

Abbott (NYSE: ABT) announced today it has received FDA clearance for its Alinity™ m STI Assay. […]

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

April 28 2022

Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize […]

Abbott Strengthens Its Connected Care Technologies with Latest Neurosphere™ Mypath™ Digital Health App

April 26 2022

Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ […]

Abbott Senior Medical Director joins Nutromics as inaugural Chief Medical Officer

April 12 2022

Australian and US MedTech start-up Nutromics (Nutromics or the Company), a global leader in DNA-based […]

Abbott Receives FDA Approval for Aveir™ Vr Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms

April 5 2022

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved […]

Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-stage Heart Failure

February 22 2022

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded […]

Abbott Announces Future of Biowearables at Consumer Electronics Show

January 7 2022

Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, […]

Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial

November 12 2021

Abbott (NYSE: ABT) today announced new, late-breaking data from the global Leadless II IDE study evaluating […]

Abbott Expands with Acquisition of Walk Vascular, LLC

September 3 2021

Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with […]

Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump

June 3 2021

Abbott today announced the company has capacity and supply to effectively support the growing demand […]

Abbott New Trial Seeks Better Treatment for AFib and Heart Failure

May 10 2021

Abbott (NYSE: ABT) today announced a new trial focused on improving the treatment for people simultaneously […]